Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7112851

Reference Type

Journal Article

Title

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

Author(s)

Schoffski, P; Lutz, CH; Folprecht, G; Seufferlein, T; Haag, C; Beutel, G; Muser, M; Marschner, JP; Kohne, CH; ,

Year

2002

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

Location

OXFORD

Page Numbers

S148-S149

Web of Science Id

WOS:000179895700499

Conference Name

14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics

Conference Location

FRANKFURT, GERMANY